Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISE trial of Arexvy immunogenicity and revaccination in elderly adults
2024-520141-23-01Phase 3Authorised
- Sponsor
- Karolinska Institutet
- Start
- Aug 2025
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of GSK3003899A in respiratory syncytial virus disease (RSV) (2 cohorts), sponsored by Karolinska Institutet. Primary endpoint: Neutralizing antibody titers against RSV A and B at day 31. Planned start Aug 2025; status: authorised.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2024-520141-23-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520141-23-01.